Search

Displaying results 5821 - 5830 of 7897 in total
  1. Drug

    CT-011

    go.drugbank.com/drugs/DB05916
    Investigational

    CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies.

  2. Drug

    INCB7839

    go.drugbank.com/drugs/DB05033
    Investigational

    INCB7839 is a novel, orally available ADAM metalloprotease inhibitor that is designed to block activation of the epidermal growth factor (EGFR) pathways. … It represents a potentially important new class of targeted breast cancer therapy. It has shown promising clinical activity in heavily pretreated, refractory breast cancer patients.

  3. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    It is a calcium antagonist with the formula methyl 2-oxopropyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate. … Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity.

  4. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236 (completed for type 1 dia...

  5. Drug

    Fluasterone

    go.drugbank.com/drugs/DB06250
    Experimental

    Has antiproliferative effects on HIV-1 and reduces HIV-1 replication.

  6. Drug

    BNC105

    go.drugbank.com/drugs/DB06313
    Investigational

  7. Drug

    Tezacitabine

    go.drugbank.com/drugs/DB06433
    Investigational

    A synthetic purine nucleoside analogue with potential antineoplastic activity.

  8. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation. … This is a novel therapeutic approach to treat kidney inflammation.

  9. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    It was studied in community patients at risk of viral infections, including SARS-CoV-2, in a terminated trial (NCT04858451) and adults with rifampicin-susceptible pulmonary tuberculosis in a recruiting … complications in surgical patients at risk of COVID-19.

  10. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose … of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).